Search

1 to 10 of 340
Sort by

Library Entry
Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma

In melanoma, there is no companion diagnostic test to predict response to programmed cell death 1 (PD-1) axis immune checkpoint inhibitor (ICI) therapy. In the adjuvant setting, only one in five patients may benefit from ICI, so a biomarker is needed to select those that may or may not benefit....


Library Entry
Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab

The authors present a case of sequential immune-related adverse events (irAEs) in a patient with metastatic melanoma treated with single-agent anti-programmed cell death-1 (PD-1) therapy, pembrolizumab. Although numerous cases of irAEs have been reported, sequential multi-organ involvement,...


Library Entry
Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature

Autoimmune polyendocrine syndrome type II (APS-2) is a rare constellation of autoimmune hypoadrenalism, thyroid dysfunction and/or type 1 diabetes (T1DM), usually occurring in the 3rd or 4th decades and associated with a human leukocyte antigen (HLA) DR3 or DR4 serotype. The authors detail the...


Library Entry
2018 Advances in Cancer Immunotherapy™ Post Program Webinar Series - Miami Webinar 2

From the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) post-program webinar recording for the Miami event is provided here. The purpose of this...

Advances in Cancer Immunotherapy™ Post-Program Webinar 2 (Miami).mp4


Library Entry
2018 Advances in Cancer Immunotherapy™ Post Program Webinar Series - Buffalo Webinar 1

From the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) post-program webinar recording for the Buffalo event is provided here. The purpose of...

Advances in Cancer Immunotherapy™ Post-Program Webinar 1 (Buffalo).mp4


Library Entry
2018 Advances in Cancer Immunotherapy™ Post Program Webinar Series - Atlanta Webinar 1

From the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) post-program webinar recording for the Atlanta event is provided here. The purpose of...

Advances in Cancer Immunotherapy™ Post-Program Webinar 1 (Atlanta).mp4


Library Entry
The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients

Despite major improvements in combating metastatic melanoma since the advent of immunotherapy, the overall survival for patients with advanced disease remains low. Recently, there is a growing number of reports supporting an “obesity paradox,” in which patients who are overweight or mildly obese...


Library Entry
Living With Melanoma Symposium – An AIM at Melanoma Foundation Resource – 2019

One cannot help but feel scared and overwhelmed after receiving a melanoma diagnosis. The challenges that patients, caregivers, family members, and friends face can be daunting and can continue even after treatment has ended. Beginning in 2010, AIM at Melanoma began partnering with nationally...


Library Entry
Living With Melanoma Symposium – An AIM at Melanoma Foundation Resource – 2018

One cannot help but feel scared and overwhelmed after receiving a melanoma diagnosis. The challenges that patients, caregivers, family members, and friends face can be daunting and can continue even after treatment has ended. Beginning in 2010, AIM at Melanoma began partnering with nationally...


Library Entry
Living With Melanoma Symposium – An AIM at Melanoma Foundation Resource – 2017

One cannot help but feel scared and overwhelmed after receiving a melanoma diagnosis. The challenges that patients, caregivers, family members, and friends face can be daunting and can continue even after treatment has ended. Beginning in 2010, AIM at Melanoma began partnering with nationally...